Therapeutic antibodies for brain disorders

Area of Science:

• Neuroscience
• Pharmacology
• Biotechnology

Background:

• Beta-secretase (BACE1) is a key target for Alzheimer's disease drug development.
• Developing BACE1 inhibitors that effectively penetrate the brain remains a significant challenge.

Purpose of the Study:

• To investigate a novel approach for enhancing brain uptake of BACE1 inhibitors.
• To evaluate the efficacy of a bispecific antibody utilizing receptor-mediated transcytosis for BACE1 inhibition.

Main Methods:

• Engineered a low-affinity bispecific monoclonal antibody targeting both BACE1 and the transferrin receptor.
• Assessed the antibody's ability to cross the blood-brain barrier and inhibit BACE1 activity in vivo.
• Compared the brain penetration and inhibitory efficiency against a monospecific BACE1 antibody.

Main Results:

• The bispecific antibody demonstrated enhanced brain entry compared to a monospecific antibody.
• The engineered antibody showed more efficient inhibition of BACE1 activity in the brain.
• Receptor-mediated transcytosis proved effective in increasing therapeutic antibody brain uptake.

Conclusions:

• Bispecific antibodies targeting the transferrin receptor can facilitate brain penetration for BACE1 inhibition.
• This strategy holds promise for developing effective treatments for Alzheimer's disease.
• Receptor-mediated transcytosis is a viable method for delivering therapeutics to the brain for various neurological disorders.